



FDP Cost Reimbursement Subaward

Federal Awarding Agency: National Institutes of Health (NIH)	
Pass-Through Entity (PTE): Fred Hutchinson Cancer Center	Subrecipient: CITY & COUNTY OF SAN FRANCISCO; DBA PUBLIC HEALTH DEPARTMENT
PTE PI: Fei Gao	Sub PI: Susan Buchbinder
PTE Federal Award No: 1 R01 AI177078-01	Subaward No: 0001148463
Project Title: Statistical Methods for Advancing HIV Prevention	
Subaward Budget Period: Start: 03/01/2023 End: 02/29/2024	Amount Funded This Action (USD): \$34,540.00
Estimated Period of Performance: Start: 03/01/2023 End: 02/29/2028	Incrementally Estimated Total (USD): \$138,160.00

Terms and Conditions

1. PTE hereby awards a cost reimbursable subaward, (as determined by 2 CFR 200.331), to Subrecipient. The Statement of Work and budget for this Subaward are as shown in Attachment 5. In its performance of Subaward work, Subrecipient shall be an independent entity and not an employee or agent of PTE.
2. Subrecipient shall submit invoices not more often than monthly and not less frequently than quarterly for allowable costs incurred. Upon the receipt of proper invoices, the PTE agrees to process payments in accordance with this Subaward and 2 CFR 200.305. All invoices shall be submitted using Subrecipient's standard invoice, but at a minimum shall include current and cumulative costs (including cost sharing), breakdown by major cost category, Subaward number, and certification, as required in 2 CFR 200.415(a). Invoices that do not reference PTE Subaward number shall be returned to Subrecipient. Invoices and questions concerning invoice receipt or payments shall be directed to the party's Financial Contact, shown in Attachment 3A.
3. ~~A final statement of cumulative costs incurred, including cost sharing, marked "FINAL" must be submitted to PTE's~~ Financial Contact, as shown in Attachment 3A, not later than 60 days after each Budget Period end date. The final statement of costs shall constitute Subrecipient's final financial report.
4. All payments shall be considered provisional and are subject to adjustment within the total estimated cost in the event such adjustment is necessary as a result of an adverse audit finding against the Subrecipient.
5. Matters concerning the technical performance of this Subaward shall be directed to the appropriate party's Principal Investigator as shown in Attachments 3A and 3B. Technical reports are required as shown in Attachment 4.
6. Matters concerning the request or negotiation of any changes in the terms, conditions, or amounts cited in this Subaward, and any changes requiring prior approval, shall be directed to the PTE's Authorized Official Contact and the Subrecipient's Authorized Official Contact shown in Attachments 3A and 3B. Any such change made to this Subaward requires the written approval of each party's Authorized Official as shown in Attachments 3A and 3B.
7. The PTE may issue non-substantive changes to the Budget Period(s) and Budget Bilaterally. Unilateral modification shall be considered valid 14 days after receipt unless otherwise indicated by Subrecipient when sent to Subrecipient's Authorized Official Contact, as shown in Attachment 3B.
8. Each party shall be responsible for its negligent acts or omissions and the negligent acts or omissions of its employees, officers, or directors, to the extent allowed by law.
9. Either party may terminate this Subaward with 30 days written notice. Notwithstanding, if the Awarding Agency terminates the Federal Award, PTE will terminate in accordance with Awarding Agency requirements. PTE notice shall be directed to the Authorized Official Contact, and Subrecipient notice shall be directed to the Authorized Official Contact as shown in Attachments 3A and 3B. PTE shall pay Subrecipient for termination costs as allowable under Uniform Guidance, 2 CFR 200, or 45 CFR Part 75 Appendix IX, as applicable.
10. By signing this Subaward, including the attachments hereto which are hereby incorporated by reference, Subrecipient certifies that it will perform the Statement of Work in accordance with the terms and conditions of this Subaward and the applicable terms of the Federal Award, including the appropriate Research Terms and Conditions ("RTCs") of the Federal Awarding Agency, as referenced in Attachment 2. The parties further agree that they intend this subaward to comply with all applicable laws, regulations, and requirements.

By an Authorized Official of the PTE:		By an Authorized Official of the Subrecipient:	
	6/8/2023		6/7/2023
Name: Alexandria Nagel	Date:	Name: Grant Colfax, MD	Date:
Title: Sponsored Research Officer, Office of Sponsored Research		Title: Director of Health	

Approved as to form, David Chiu, City Attorney

By:  DocuSigned by:

Henry L. Lifton, Deputy City Attorney

FDP DEC 2020

Attachment 1

Certifications and Assurances

Subaward Number:

0001148463

Certification Regarding Lobbying (2 CFR 200.450)

By signing this Subaward, the Subrecipient Authorized Official certifies, to the best of his/her knowledge and belief, that no Federal appropriated funds have been paid or will be paid, by or on behalf of the Subrecipient, to any person for influencing or attempting to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with the awarding of any Federal contract, the making of any Federal grant, the making of any Federal loan, the entering into of any cooperative agreement, and the extension, continuation, renewal, amendment, or modification of any Federal contract, grant, loan, or cooperative agreement in accordance with 2 CFR 200.450.

If any funds other than Federal appropriated funds have been paid or will be paid to any person for influencing or intending to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with this Federal contract, grant, loan, or cooperative agreement, the Subrecipient shall complete and submit Standard Form -LLL, "Disclosure Form to Report Lobbying," to the PTE.

This certification is a material representation of fact upon which reliance was placed when this transaction was made or entered into. Submission of this certification is a prerequisite for making or entering into this transaction imposed by 31 U.S.C. 1352. Any person who fails to file the required certification shall be subject to a civil penalty of not less than \$10,000 and not more than \$100,000 for each such failure.

Debarment, Suspension, and Other Responsibility Matters (2 CFR 200.214 and 2 CFR 180)

By signing this Subaward, the Subrecipient Authorized Official certifies, to the best of his/her knowledge and belief that neither the Subrecipient nor its principals are presently debarred, suspended, proposed for debarment, declared ineligible or voluntarily excluded from participation in this transaction by any federal department or agency, in accordance with 2 CFR 200.213 and 2 CFR 180.

Audit and Access to Records

Subrecipient certifies that it will provide PTE with notice of any adverse findings which impact this Subaward. Subrecipient certifies compliance with applicable provisions of 2 CFR 200.501-200.521. If Subrecipient is not required to have a Single Audit as defined by 200.501, Awarding Agency requirements, or the Single Audit Act, then Subrecipient will provide notice of the completion of any required audits and will provide access to such audits upon request. Subrecipient will provide access to records as required by parts 2 CFR 200.337 and 200.338 as applicable.

Program for Enhancement of Contractor Employee Protections (41 U.S.C 4712)

Subrecipient is hereby notified that they are required to: inform their employees working on any federal award that they are subject to the whistleblower rights and remedies of the program; inform their employees in writing of employee whistleblower protections under 41 U.S.C §4712 in the predominant native language of the workforce; and include such requirements in any agreement made with a subcontractor or subgrantee.

The Subrecipient shall require that the language of the certifications above in this Attachment 1 be included in the award documents for all subawards at all tiers (including subcontracts, subgrants, and contracts under grants, loans, and cooperative agreements) and that all subrecipients shall certify and disclose accordingly.

Use of Name

Neither party shall use the other party's name, trademarks, or other logos in any publicity, advertising, or news release without the prior written approval of an authorized representative of that party. The parties agree that each party may use factual information regarding the existence and purpose of the relationship that is the subject of this Subaward for legitimate business purposes, to satisfy any reporting and funding obligations, or as required by applicable law or regulation without written permission from the other party. In any such statement, the relationship of the parties shall be accurately and appropriately described.

Prohibition on Certain Telecommunication and Video Surveillance Services or Equipment

Pursuant to 2 CFR 200.216, Subrecipient will not obligate or expend funds received under this Subaward to: (1) procure or obtain; (2) extend or renew a contract to procure or obtain; or (3) enter into a contract (or extend or renew a contract) to procure or obtain equipment, services, or systems that uses covered telecommunications equipment or services (as described in Public Law 115-232, section 889) as a substantial or essential component of any system, or as a critical technology as part of any system.

Attachment 2

Federal Award Terms and Conditions

Subaward Number

0001148463

Required Data Elements

The data elements required by Uniform
Guidance are incorporated in the attached Federal Award.

Awarding Agency Institute (If Applicable)

Federal Award Issue Date	FAIN	Assistance Listing No.
03/01/2023	R01AI177078	93.855

Assistance Listing Program Title (ALPT)

Allergy and Infectious Diseases Research

Key Personnel Per NOA

This Subaward Is:

☒ Research & Development ☐ Subject to FFATA

General Terms and Conditions

By signing this Subaward, Subrecipient agrees to the following:

- To abide by the conditions on activities and restrictions on expenditure of federal funds in appropriations acts that are applicable to this Subaward to the extent those restrictions are pertinent. This includes any recent legislation noted on the Federal Awarding Agency's website:
<http://grants.nih.gov/policy/notices.htm>
- 2 CFR 200 and 45 CFR Part 75.
- The Federal Awarding Agency's grants policy guidance, including addenda in effect as of the beginning date of the period of performance or as amended found at:
<http://grants.nih.gov/grants/policy/nihgps/nihgps.pdf>
- Research Terms and Conditions, including any Federal Awarding Agency's Specific Requirements found at:
<https://www.nsf.gov/awards/managing/rtr.jsp> except for the following :
 - No-cost extensions require the written approval of the PTE. Any requests for a no-cost extension shall be directed to the **Administrative** Contact shown in Attachment 3A, not less than 30 days prior to the desired effective date of the requested change.
 - Any payment mechanisms and financial reporting requirements described in the applicable Federal Awarding Agency Terms and Conditions and Agency-Specific Requirements are replaced with Terms and Conditions (1) through (4) of this Subaward; and
 - Any prior approvals are to be sought from the PTE and not the Federal Awarding Agency.
 - Title to equipment as defined in 2 CFR 200.1 that is purchased or fabricated with research funds or Subrecipient cost sharing funds, as direct costs of the project or program, shall vest in the Subrecipient subject to the conditions specified in 2 CFR 200.313.
 - Prior approval must be sought for a change in Subrecipient PI or change in Key Personnel (defined as listed on the NOA).
- Treatment of program income: **Additive**

Special Terms and Conditions:**Data Sharing and Access:**

Subrecipient agrees to comply with the Federal Awarding Agency's data sharing and/or access requirements as reflected in the NOA or the Federal Awarding Agency's standard terms and conditions as referenced in General Terms and Conditions 1-4 above.

No additional requirements

Data Rights:

Subrecipient grants to PTE the right to use data created in the performance of this Subaward solely for the purpose of and only to the extent required to meet PTE's obligations to the Federal Government under its PTE Federal Award.

Copyrights:

Subrecipient Shall Grant to PTE an irrevocable, royalty-free, non-transferable, non-exclusive right and license to use, reproduce, make derivative works, display, and perform publicly any copyrights or copyrighted material (including any computer software and its documentation and/or databases) first developed and delivered under this Subaward solely for the purpose of and only to the extent required to meet PTE's obligations to the Federal Government under its PTE Federal Award.

Subrecipient grants to PTE the right to use any written progress reports and deliverables created under this Subaward solely for the purpose of and only to the extent required to meet PTE's obligations to the Federal Government under its Federal Award.

Promoting Objectivity in Research (COI):

Subrecipient must designate herein which entity's Financial Conflicts of Interest policy (COI) will apply: **Subrecipient**

If applying its own COI policy, by execution of this Subaward, Subrecipient certifies that its policy complies with the requirements of the relevant Federal Awarding Agency as identified herein: **NIH - 42 CFR Part 50 Subpart F**

Subrecipient shall report any financial conflict of interest to PTE's Administrative Representative or COI contact, as designated on Attachment 3A. Any financial conflicts of interest identified shall, when applicable, subsequently be reported to Federal Awarding Agency. Such report shall be made before expenditure of funds authorized in this Subaward and within 45 days of any subsequently identified COI.

Work Involving Human or Vertebrate Animals (Select Applicable Options)

☒ No Human or Vertebrate Animals

This section left intentionally blank.

Human Subjects Data (Select One)

This section left intentionally blank

NIH Terms and Conditions

The Clinical Trial Indicator in Section IV of the PTE's NOA is stated as:

Multiple PIs (MPI)

Certificate of Confidentiality:

The Parties agree that this research funded in whole or in part by the National Institutes of Health ("NIH"), is subject to NIH Policy NOT-OD-17-109 (the "Policy") and therefore is deemed under the Policy to be issued a Certificate of Confidentiality ("Certificate") should the conditions outlined within the Policy apply. Accordingly, the subrecipients who collect or receive identifiable, sensitive information are required to adhere to the Policy and protect the privacy of individuals who are subjects of such research in accordance with the Policy and subsection 301(d) of the Public Health Service Act (the "PHS Act").

Additional Terms

Consortium Agreement. Subrecipient may not transfer any funds issued under this Subaward to another organization for the purposes of carrying out any portion of the planned programmatic activities in the form of a Consortium Agreement. A Consortium Agreement is a formalized agreement whereby a research project is carried out by the grantee and one or more other organizations that are separate legal entities. The referenced section of the NIH Grants Policy Statement is available at:

https://grants.nih.gov/grants/policy/nihgps/HTML5/section_15/15_consortium_agreements.htm#

Attachment 3A**Research Subaward Agreement
Pass-Through Entity (PTE) Contacts**

Subaward Number:

0001148463

PTE Information

Entity Name: Fred Hutchinson Cancer Center

Legal Address: 1100 Fairview Ave N
Seattle, WA 98109

Website: www.fredhutch.org

PTE Contacts

Central Email: [REDACTED]

Principal Investigator Name: Fei Gao

Email: [REDACTED]

Telephone Number: [REDACTED]

Administrative Contact Name: Alexandria Nagel

Email: [REDACTED]

Telephone Number: [REDACTED]

COI Contact email (if different to above): [REDACTED]

Financial Contact Name: Accounts Payable

Email: [REDACTED]

Telephone Number: [REDACTED]

Email invoices? ☒ Yes ☐ No Invoice email (if different): [REDACTED]

Authorized Official Name: Shannon K. Lysen

Email: [REDACTED]

Telephone Number: [REDACTED]

PI Address:FRED HUTCHINSON CANCER CENTER
1100 Fairview Ave N
Seattle, WA 98109**Administrative Address:**FRED HUTCHINSON CANCER CENTER
1100 Fairview Ave N
Mail Stop J6-500
Seattle, WA 98109**Invoice Address:**FRED HUTCHINSON CANCER CENTER
1100 Fairview Ave N
Mail Stop J4-500
Seattle, WA 98109

Attachment 3B**Research Subaward Agreement
Subrecipient Contacts**

Subaward Number:

0001148463

Subrecipient Information for FFATA reporting

Entity's UEI/DUNS Name: CITY & COUNTY OF SAN FRANCISCO; DBA PUBLIC HEALTH DEPARTMENT

EIN No.: 94-6000417 Institution Type: County Government

UEI / DUNS: DCTNHRGU1K75 Currently registered in SAM.gov: ☒ Yes ☐ NoParent UEI / DUNS: Exempt from reporting executive compensation: Yes ☒ No ☐
(if no, complete 3B pg2)**Place of Performance Information for FFATA reporting**

Physical Address, City, State (if U.S.) and Country:

25 Van Ness, Suite 500
San Francisco, CA 94102**U.S. Entities only (insert information for Place of Performance):**

Congressional District: CA-12 Zip Code+4: 94102-4505

[Zip Code Look-up](#)**Subrecipient Contacts**

Central Email:

Website:

Principal Investigator Name: Susan Buchbinder

Email:

Telephone Number:

Administrative Contact Name: Eduardo Sida

Email:

Telephone Number:

Financial Contact Name: Sajid Shaikh

Email:

Telephone Number:

Invoice Email:

Authorized Official Name: Greg Wagner

Email:

Telephone Number:

Legal Address:101 Grove Street
San Francisco, CA 94103**Administrative Address:**1380 Howard Street, 4th Floor
San Francisco, CA 94103**Payment Address:**1380 Howard Street, 4th Floor
San Francisco, CA 94103

Attachment 3B-2

Highest Compensated Officers

Subaward Number:

0001148463

Subrecipient:

Institution Name: CITY & COUNTY OF SAN FRANCISCO; DBA PUBLIC HEALTH DEPARTMENT

PI Name: Susan Buchbinder

Highest Compensated Officers

The names and total compensation of the five most highly compensated officers of the entity(ies) must be listed if the entity in the preceding fiscal year received 80 percent or more of its annual gross revenues in Federal awards; and \$25,000,000 or more in annual gross revenues from Federal awards; and the public does not have access to this information about the compensation of the senior executives of the entity through periodic reports filed under section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. §§ 78m(a), 78o(d)) or section 6104 of the Internal Revenue Code of 1986. See FFATA § 2(b)(1) Internal Revenue Code of 1986.

Officer 1 Name:

Officer 1 Compensation:

Officer 2 Name:

Officer 2 Compensation:

Officer 3 Name:

Officer 3 Compensation:

Officer 4 Name:

Officer 4 Compensation:

Officer 5 Name:

Officer 5 Compensation:

Attachment 4
Reporting and Prior Approval Terms

Subaward Number:

0001148463

Subrecipient agrees to submit the following reports (PTE contacts are identified in Attachment 3A):

Technical Reports:

- ☐ Monthly technical/progress reports will be submitted to the PTE's Administrative Contact within 30 days of the end of the month.
- ☐ Quarterly technical/progress reports will be submitted within 30 days after the end of each project quarter to the PTE's Administrative Contact.
- ☒ Annual technical / progress reports will be submitted within 30 days prior to the end of each budget period to the PTE's Principal Investigator. Such report shall also include a detailed budget for the next Budget Period, updated other support for key personnel, certification of appropriate education in the conduct of human subject research of any new key personnel, and annual IRB or IACUC approval, if applicable.
- ☒ A Final technical/progress report will be submitted to the PTE's Principal Investigator within 60 days of the end of the Project Period or after termination of this award, whichever comes first.
- ☒ Technical/progress reports on the project as may be required by PTE's Principal Investigator in order for the PTE to satisfy its reporting obligations to the Federal Awarding Agency.

Prior Approvals:

Carryover:

Carryover is automatic**Other Reports:**

- ☒ In accordance with 37 CFR 401.14, Subrecipient agrees to notify both the Federal Awarding Agency via iEdison and PTE's Administrative Contact within 60 days after Subrecipient's inventor discloses invention(s) in writing to Subrecipient's personnel responsible for patent matters. The Subrecipient will submit a final invention report using Federal Awarding Agency specific forms to the PTE's Administrative Contact within 60 days of the end of the Project Period to be included as part of the PTE's final invention report to the Federal Awarding Agency.

A negative report is required: No

- ☐ Property Inventory Report (only when required by Federal Awarding Agency), specific requirements below.

Additional Technical and Reporting Requirements:

Attachment 5

Statement of Work, Cost Sharing, Indirects & Budget

Subaward Number:

0001148463

Statement of Work

☒ Below ☐ Attached, pages

If award is FFATA eligible and SOW exceeds 4000 characters, include a *Subrecipient Federal Award Project Description*

On this project, Dr. Buchbinder will serve as a clinical expert. She will help to identify logistical/implementation and clinical issues pertinent to evaluating HIV incidence with recency testing data (Specific Aim 1), and clinical considerations pertinent to trial design and efficacy evaluation under Specific Aim 2. She will provide collaboration and input on the application of these approaches to existing datasets. She will assist in the dissemination and application of the proposed methods to future HIV prevention trials.

Budget Information

Indirect Information	Indirect Cost Rate (IDC) Applied <input type="text" value="24.678"/> %	Cost Sharing	<input type="text" value="No"/>
Rate Type: <input type="text" value="Modified Total Direct Costs"/>	<input type="text"/>	If Yes, include Amount: \$	<input type="text"/>

Budget Details ☐ Below ☒ Attached, pages

Exhibit A, Budget-Cost Reimbursement follows.

§200.332(a)(1)(viii) Total Amount of Federal Funds Obligated to the subrecipient by the pass-through entity including the current financial obligation:

\$

Budget Totals

Direct Costs	\$	<input type="text" value="27,703.00"/>
Indirect Costs	\$	<input type="text" value="6,837.00"/>
Total Costs	\$	<input type="text" value="34,540.00"/>

All amounts are in United States Dollars

Exhibit A of Attachment 5

Budget – Cost Reimbursement

Category		Budget
Direct Labor	\$	20,370.00
Fringe Benefits		7,333.00
Consultants		0.00
Subcontracts		0.00
Equipment		0.00
Supplies		0.00
Patient Care		0.00
Tuition		0.00
Travel		0.00
Other		0.00
Total Direct Costs	\$	27,703.00
Indirect Costs	F&A Rate: 24.678 %	\$ 6,837.00
Total Costs	\$	34,540.00

Attachment 6

Notice of Award (NOA) and any additional documents



The following pages include the NOA and if applicable any additional documentation referenced throughout this Subaward.



Not incorporating the NOA or any additional documentation to this Subaward.



Recipient Information

1. Recipient Name

FRED HUTCHINSON CANCER CENTER
1100 FAIRVIEW AVE N

SEATTLE, 98109

2. Congressional District of Recipient
07

3. Payment System Identifier (ID)
1911935159A2

4. Employer Identification Number (EIN)
911935159

5. Data Universal Numbering System (DUNS)
806433145

6. Recipient's Unique Entity Identifier
TJFZLPP6NYL6

7. Project Director or Principal Investigator
Fei Gao, PHD

8. Authorized Official
Shannon K Lysen

Federal Agency Information

9. Awarding Agency Contact Information
LILIETH A Campbell
Grant Management Specialist
NATIONAL INSTITUTE OF ALLERGY AND
INFECTIOUS DISEASES

10. Program Official Contact Information
Misrak Gezmu
Program Official
NATIONAL INSTITUTE OF ALLERGY AND
INFECTIOUS DISEASES

Federal Award Information

11. Award Number
1R01AI177078-01

12. Unique Federal Award Identification Number (FAIN)
R01AI177078

13. Statutory Authority
42 USC 241 42 CFR 52

14. Federal Award Project Title
Statistical Methods for Advancing HIV Prevention

15. Assistance Listing Number
93.855

16. Assistance Listing Program Title
Allergy and Infectious Diseases Research

17. Award Action Type
New Competing

18. Is the Award R&D?
Yes

Summary Federal Award Financial Information

19. Budget Period Start Date 03/01/2023 – End Date 02/29/2024

20. Total Amount of Federal Funds Obligated by this Action	\$431,018
20 a. Direct Cost Amount	\$256,837
20 b. Indirect Cost Amount	\$174,181

21. Authorized Carryover

22. Offset

23. Total Amount of Federal Funds Obligated this budget period	\$431,018
---	-----------

24. Total Approved Cost Sharing or Matching, where applicable	\$0
--	-----

25. Total Federal and Non-Federal Approved this Budget Period	\$431,018
--	-----------

26. Project Period Start Date 03/01/2023 – End Date 02/29/2028

27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period	\$431,018
--	-----------

28. Authorized Treatment of Program Income
Additional Costs

29. Grants Management Officer - Signature
Sufiyan Saeed

30. Remarks

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.



RESEARCH
Department of Health and Human Services
National Institutes of Health

Notice of Award



NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

SECTION I – AWARD DATA – 1R01AI177078-01**Principal Investigator(s):**

Fei Gao, PHD

Dear Authorized Official:

The National Institutes of Health hereby awards a grant in the amount of \$431,018 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to FRED HUTCHINSON CANCER CENTER in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R01AI177078. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please direct questions to the Federal Agency contacts.

Sincerely yours,

Sufiyan Saeed
Grants Management Officer
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Additional information follows

Cumulative Award Calculations for this Budget Period (U.S. Dollars)

Federal Direct Costs	\$256,837
Federal F&A Costs	\$174,181
Approved Budget	\$431,018
Total Amount of Federal Funds Authorized (Federal Share)	\$431,018
TOTAL FEDERAL AWARD AMOUNT	\$431,018
 AMOUNT OF THIS ACTION (FEDERAL SHARE)	 \$431,018

SUMMARY TOTALS FOR ALL YEARS (for this Document Number)		
YR	THIS AWARD	CUMULATIVE TOTALS
1	\$431,018	\$431,018
2	\$412,018	\$412,018
3	\$412,018	\$412,018
4	\$419,125	\$419,125
5	\$419,125	\$419,125

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

Payment System Identifier: 1911935159A2
Document Number: RAI177078A
PMS Account Type: P (Subaccount)
Fiscal Year: 2023

IC	CAN	2023	2024	2025	2026	2027
AI	8472325	\$431,018	\$412,018	\$412,018	\$419,125	\$419,125

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: A20 / **OC:** 41021 / **Released:** Saeed, Sufiyan 02/17/2023
Award Processed: 03/01/2023 12:14:26 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 1R01AI177078-01

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – STANDARD TERMS AND CONDITIONS – 1R01AI177078-01

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Award.
- Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- 45 CFR Part 75.
- National Policy Requirements and all other requirements described in the NIH Grants Policy

- Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
 - f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

This institution is a signatory to the Federal Demonstration Partnership (FDP) Phase VII Agreement which requires active institutional participation in new or ongoing FDP demonstrations and pilots.

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to obtain a unique entity identifier (UEI) and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a UEI requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01AI177078. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

Recipients must administer the project in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age, and comply with applicable conscience protections. The recipient will comply with applicable laws that prohibit discrimination on the basis of sex, which includes discrimination on the basis of gender identity, sexual orientation, and pregnancy. Compliance with these laws requires taking reasonable steps to provide meaningful access to persons with limited English proficiency and providing programs that are accessible to and usable by persons with disabilities. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. See <https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html> and <https://www.hhs.gov/>.

- Recipients of FFA must ensure that their programs are accessible to persons with limited English

- proficiency. For guidance on meeting the legal obligation to take reasonable steps to ensure meaningful access to programs or activities by limited English proficient individuals, see <https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/fact-sheet-guidance/index.html> and <https://www.lep.gov>.
- For information on an institution's specific legal obligations for serving qualified individuals with disabilities, including providing program access, reasonable modifications, and to provide effective communication, see <http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html>.
 - HHS funded health and education programs must be administered in an environment free of sexual harassment; see <https://www.hhs.gov/civil-rights/for-individuals/sex-discrimination/index.html>. For information about NIH's commitment to supporting a safe and respectful work environment, who to contact with questions or concerns, and what NIH's expectations are for institutions and the individuals supported on NIH-funded awards, please see <https://grants.nih.gov/grants/policy/harassment.htm>.
 - For guidance on administering programs in compliance with applicable federal religious nondiscrimination laws and applicable federal conscience protection and associated anti-discrimination laws, see <https://www.hhs.gov/conscience/conscience-protections/index.html> and <https://www.hhs.gov/conscience/religious-freedom/index.html>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

Treatment of Program Income:

Additional Costs

SECTION IV – AI SPECIFIC AWARD CONDITIONS – 1R01AI177078-01

Clinical Trial Indicator: No

This award does not support any NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

This is a Modular Award without direct cost categorical breakdowns in accordance with the guidelines published in the NIH Grants Policy Statement, see https://grants.nih.gov/grants/policy/nihgps/HTML5/section_13/13.5_post-award_administration.htm.

Recipients are required to allocate and account for costs related to this award by category within their institutional accounting system in accordance with applicable cost principles.

This Notice of Award (NoA) includes funds for **The City and County of San Francisco**.

REMINDER: This grant is funded for HIV/AIDS research. Per the NIH Revitalization Act of 1993, funds are restricted for HIV/AIDS research and cannot be re-budgeted for other purposes.

SPREADSHEET SUMMARY

AWARD NUMBER: 1R01AI177078-01

INSTITUTION: FRED HUTCHINSON CANCER CENTER

Budget	Year 1	Year 2	Year 3	Year 4	Year 5
TOTAL FEDERAL DC	\$256,837	\$256,837	\$256,837	\$253,418	\$253,418
TOTAL FEDERAL F&A	\$174,181	\$155,181	\$155,181	\$165,707	\$165,707
TOTAL COST	\$431,018	\$412,018	\$412,018	\$419,125	\$419,125

Facilities and Administrative Costs	Year 1	Year 2	Year 3	Year 4	Year 5
F&A Cost Rate 1	76%	76%	76%	76%	76%
F&A Cost Base 1	\$229,185	\$204,185	\$204,185	\$218,036	\$218,036
F&A Costs 1	\$174,181	\$155,181	\$155,181	\$165,707	\$165,707